NYSE : ABT
Abbott Laboratories — Key statistics
Healthcare · Medical Devices · United States
Last price 106.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 183.77B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 183.77B |
| Enterprise Value | 210.88B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 21, 2026 |
| Ex-Dividend Date | Oct 15, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.73B |
| Shares Outstanding | 1.73B |
| Shares Change (YoY) | -0.25% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.48% |
| Owned by Institutions (%) | 80.98% |
| Float | 1.72B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 39.47 |
| Forward PE | 18.20 |
| PS Ratio | 3.81 |
| Forward PS | 3.48 |
| PB Ratio | 3.60 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 23.49 |
| P/OCF Ratio | 18.55 |
| PEG Ratio | 1.94 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 45.09 |
| EV / Sales | 4.37 |
| EV / EBITDA | 17.64 |
| EV / EBIT | 26.42 |
| EV / FCF | 26.95 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.38 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 2.65 |
| Debt / FCF | 4.18 |
| Interest Coverage | 7.87 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 10.58% |
| Return on Assets (ROA) | 5.33% |
| Return on Invested Capital (ROIC) | 7.25% |
| Return on Capital Employed (ROCE) | 9.01% |
| Weighted Average Cost of Capital (WACC) | 6.67% |
| Revenue Per Employee | $395,320 |
| Profits Per Employee | $38,336 |
| Employee Count | 122,000 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 2.82 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.86B |
| Effective Tax Rate | 28.36% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -14.65% |
| 50-Day Moving Average | 104.34 |
| 200-Day Moving Average | 101.69 |
| Relative Strength Index (RSI) | 59.52 |
| Average Volume (20 Days) | 9,872,532 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 17.39M |
| Short Previous Month | 19.91M |
| Short % of Shares Out | 1.00% |
| Short % of Float | 1.01% |
| Short Ratio (days to cover) | 1.84 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 48.23B |
| Gross Profit | 27.53B |
| Operating Income | 7.98B |
| Pretax Income | 6.56B |
| Net Income | 4.68B |
| EBITDA | 11.95B |
| EBIT | 7.98B |
| Earnings Per Share (EPS) | $2.69 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.60B |
| Total Debt | 32.72B |
| Net Cash | -27.12B |
| Net Cash Per Share | -$15.67 |
| Equity (Book Value) | 51.76B |
| Book Value Per Share | 29.54 |
| Working Capital | 6.70B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 9.91B |
| Capital Expenditures | -2.08B |
| Depreciation & Amortization | 3.97B |
| Net Borrowing | 16.54B |
| Free Cash Flow | 7.82B |
| FCF Per Share | $4.52 |
Margins
| Measure | Value |
|---|
| Gross Margin | 57.08% |
| Operating Margin | 16.55% |
| Pretax Margin | 13.61% |
| Profit Margin | 9.75% |
| EBITDA Margin | 24.79% |
| EBIT Margin | 16.55% |
| FCF Margin | 16.80% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $2.52 |
| Dividend Yield | 2.37% |
| Dividend Growth (YoY) | 6.78% |
| Years of Dividend Growth | 54 |
| Payout Ratio | 93.66% |
| FCF Payout Ratio | 55.73% |
| Buyback Yield | 0.25% |
| Shareholder Yield | 2.62% |
| Earnings Yield | 2.53% |
| FCF Yield | 4.26% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $118.52 |
| Price Target Difference | 11.60% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 8.70% |
| EPS Growth Forecast (3Y) | 8.12% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 1, 1998 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |